Monoclonal antibody therapy of human malignancies is infrequently associated with either clinical responses or inflammatory infiltrates in tumor that are composed of tumoricidal effector cells. Antibody-dependent cellular cytotoxicity (APCC), a potent in vitro tumoricidal mechanism, appears to be less important in eradicating tumors in vivo. New strategies that exploit the ability of murine antibodies to target tumor cells and interact with tumoricidal host effector cells are needed. Antibodies that mind to effector cells and trigger cytotoxicity via either 1) the C03 molecule or antigen receptor on T cells, 2) the Fcy receptor for aggregated immunoglobulin expressed by large Sranuler lymphocytes (LGL's) or 3) the high affinity Fcy receptor expressed by mononuclear phagocytes have teen identified. Such antibodies, when chemically linked to anti-tumor antibodies, potentiate in vitro tumor lysis by the relevant effector cells. In contrast to ADCC, these effects are resistant to competition by excess human immunoglobulin. The present proposal provides for the preparation of be specific monoclonal antibodies, derived by cell fusion, that bind tumor-associated antigens and the Fcy receptor (FcyR III) expressed by LGL's, a potent cytotoxic cell population. These antibodies promote high affinity interactions between tumor targets and affecters and trigger effector cell cytotoxicity. Conditions that promote optimal in vitro bispecific antibody-mediated lysis of relevant tumor cells by interleukin-2 activated peripheral blood mononucluar cells and LGL's will be identified. The ability of these antibodies to focus LGL's at tumor sites and mediate tumor regression will bs tested in vivo using a human tumor xenograft model in nude mice. A syngeneic tumor model using bispecific antibodies containing anti-murine FcyR II specificity will also be developed since interpretation of results in a human tumor xenograft model that uses human effector cells may be difficult. These studies will provide insight into those factors that promote bispecific antibody-mediated inflammatory infiltrates in tumor, the relevance of these infiltrates to anti-tumor effects and the potential of this approach in the treatment of human malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA050633-01
Application #
3195257
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1989-06-01
Project End
1992-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
1
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207
Aldeghaither, Dalal S; Zahavi, David J; Murray, Joseph C et al. (2018) A Mechanism of Resistance to Antibody-Targeted Immune Attack. Cancer Immunol Res :
Shuptrine, Casey W; Ajina, Reham; Fertig, Elana J et al. (2017) An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. Cancer Immunol Immunother 66:1529-1544
Berens, E B; Sharif, G M; Schmidt, M O et al. (2017) Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion. Oncogene 36:593-605
Varghese, Rency S; Zuo, Yiming; Zhao, Yi et al. (2017) Protein network construction using reverse phase protein array data. Methods 124:89-99
Zhang, Yong-Wei; Nasto, Rochelle E; Jablonski, Sandra A et al. (2017) RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio Protoc 7:
Murakami, S; Shahbazian, D; Surana, R et al. (2017) Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene 36:1232-1244
Gibney, Geoffrey T; Weiner, Louis M; Atkins, Michael B (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542-e551
Zhang, Y-W; Nasto, R E; Varghese, R et al. (2016) Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. Oncogene 35:1643-56
Redman, J M; Hill, E M; AlDeghaither, D et al. (2015) Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol 67:28-45

Showing the most recent 10 out of 58 publications